Duvelisib Response Rate ' Exciting ' in Patients With r/r PTCL Duvelisib Response Rate ' Exciting ' in Patients With r/r PTCL

Duvelisib is demonstrating encouraging activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) in a phase 2 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news